Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare ovarian tumors: targeted drugs under study

NCT ID NCT04931342

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing several targeted drugs in people with rare types of ovarian cancer that have come back or not gone away. The drugs are chosen based on specific biomarkers in each patient's tumor. The goal is to see if these treatments can shrink or control the cancer. About 176 participants will receive one of four drugs: ipatasertib, cobimetinib, trastuzumab emtansine, or atezolizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab
What this could lead to
If successful, this could provide effective treatment options for people with rare ovarian cancers that have returned or not responded to standard therapy.
What could go wrong
This is an early-phase study with a small number of participants. The drugs may not work for all tumor types, and side effects could limit their use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

  • A.O. U. Consorziale Policlinico di Bari

    Bari, Apulia, 70124, Italy

  • Adana Baskent University Medical Faculty; Oncology

    Adana, 01220, Turkey (Türkiye)

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü

    Ankara, 06490, Turkey (Türkiye)

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • Cabrini Hospital

    Malvern, Victoria, 3144, Australia

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Groupe Hospitalier Diaconesses

    Paris, 75020, France

  • Gustave Roussy

    Villejuif, 94800, France

  • Gynekologicko-porodnicka klinika

    Prague, 120 00, Czechia

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hôpitaux Universitaires de Genève

    Geneva, 1205, Switzerland

  • ICO - Site René Gauducheau

    Saint-Herblain, 44805, France

  • IRCCS S. Raffaele

    Milan, Lombardy, 20132, Italy

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • Institutio Catalan De Oncologia

    Barcelona, 08908, Spain

  • Istituto Tumori Napoli

    Naples, Campania, 80131, Italy

  • Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie

    Essen, 45136, Germany

  • Koc University Medical Faculty; Department of Gynecology & Obstetrics

    Istanbul, 34010, Turkey (Türkiye)

  • LLC Medscan

    Moskva, Moscow Oblast, 119421, Russia

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, H4A 3J1, Canada

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, 00168, Italy

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 1Z5, Canada

  • Samsung Medical Center

    Seoul, (0)6351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Texas Oncology - Gulf Coast

    The Woodlands, Texas, 77380, United States

  • UCSF Helen Diller Family CCC

    San Francisco, California, 94158, United States

  • University College London Hospitals NHS Foundation Trust - University College Hospital

    London, NW1 2PG, United Kingdom

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Washington - Seattle Cancer Care Alliance

    Seattle, Washington, 98109, United States

  • Universitätsklinikum Mannheim

    Mannheim, 68167, Germany

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63108, United States

  • Western General Hospital

    Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.